We are live on
!
Find out more
CLOS
Compagnie Lombard Odier SCmA Portfolio holdings
AUM
$9.25B
1-Year Est. Return
27.04%
This Fund
S&P 500
This Quarter
Est. Return
+9.36%
1 Year Est. Return
+27.04%
3 Year Est. Return
+108.78%
5 Year Est. Return
+129.43%
10 Year Est. Return
+503.05%
AUM
$4.55B
AUM Growth
+$12.4M
(+0.27%)
Cap. Flow
-$345M
Cap. Flow
% of AUM
-7.59%
Top 10 Holdings %
Top 10 Hldgs %
40.84%
Holding
720
New
73
Increased
111
Reduced
146
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$46.3M |
| 2 |
Blackrock
BLK
|
+$25.5M |
| 3 |
Sea Limited
SE
|
+$21.7M |
| 4 |
ServiceNow
NOW
|
+$21.2M |
| 5 |
Estee Lauder
EL
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intellia Therapeutics
NTLA
|
+$22M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$20.4M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$19.4M |
| 4 |
Allogene Therapeutics
ALLO
|
+$18.9M |
| 5 |
10x Genomics
TXG
|
+$17.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.67% |
| 2 | Communication Services | 18.56% |
| 3 | Financials | 15.44% |
| 4 | Consumer Discretionary | 14.23% |
| 5 | Healthcare | 14.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Crown Holdings
CCK
$13B
| $79K | ﹤0.01% |
775
-6,615
| -90% | -$697K |
|
427
Equifax
EFX
$21.4B
| $79K | ﹤0.01% |
330
| – | – |
|
428
iShares S&P 100 ETF
OEF
$20.5B
| $78K | ﹤0.01% |
+400
| New | +$76K |
|
429
Vertex Pharmaceuticals
VRTX
$134B
| $76K | ﹤0.01% |
380
+130
| +52% | +$27.2K |
|
430
Gartner
IT
$12B
| $75K | ﹤0.01% |
310
| – | – |
|
431
Upstart Holdings
UPST
$2.98B
| $75K | ﹤0.01% |
+600
| New | +$73.8K |
|
432
Invesco Solar ETF
TAN
$1.36B
| $74K | ﹤0.01% |
+830
| New | +$67.5K |
|
|
CVAC
433
DELISTED
CureVac
CVAC
| $73K | ﹤0.01% |
1,000
-1,475
| -60% | -$147K |
|
434
Itaú Unibanco
ITUB
$87.4B
| $73K | ﹤0.01% |
16,723
| – | – |
|
435
Public Service Enterprise Group
PEG
$37.2B
| $73K | ﹤0.01% |
1,216
| – | – |
|
436
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
$23.3B
| $71K | ﹤0.01% |
+1,300
| New | +$71.2K |
|
437
Citizens Financial Group
CFG
$30.5B
| $70K | ﹤0.01% |
1,521
| – | – |
|
438
Trade Desk
TTD
$6.14B
| $70K | ﹤0.01% |
900
+400
| +80% | +$25.6K |
|
|
CTRA
439
DELISTED
Coterra Energy
CTRA
| $69K | ﹤0.01% |
+3,927
| New | +$66.8K |
|
440
Principal Financial Group
PFG
$24.3B
| $69K | ﹤0.01% |
1,090
| – | – |
|
441
Ross Stores
ROST
$82.1B
| $69K | ﹤0.01% |
555
-5,300
| -91% | -$661K |
|
442
Zimmer Biomet
ZBH
$18.4B
| $69K | ﹤0.01% |
443
| – | – |
|
443
First Majestic Silver
AG
$9.27B
| $67K | ﹤0.01% |
4,200
| – | – |
|
444
BP
BP
$110B
| $66K | ﹤0.01% |
+2,482
| New | +$65.1K |
|
445
Lam Research
LRCX
$386B
| $66K | ﹤0.01% |
1,020
+700
| +219% | +$44.2K |
|
446
Pinduoduo
PDD
$132B
| $66K | ﹤0.01% |
+520
| New | +$67.6K |
|
|
447
Tandem Diabetes Care
TNDM
$1.57B
| $65K | ﹤0.01% |
670
-228,331
| -100% | -$20.4M |
|
448
BCE
BCE
$21B
| $63K | ﹤0.01% |
1,280
| – | – |
|
|
TWTR
449
DELISTED
Twitter, Inc.
TWTR
| $62K | ﹤0.01% |
900
-100
| -10% | -$6.13K |
|
|
HRC
450
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $62K | ﹤0.01% |
+550
| New | +$61.6K |
|
Similar funds
SUT
HKAM
LCAM
IAA
WPL
PVI
AC
SFM
Compagnie Lombard Odier SCmA's Q2 2021 Portfolio in Review
As of Q2 2021, Compagnie Lombard Odier SCmA held 720 positions worth $4.55B, up 0.27% from $4.54B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Compagnie Lombard Odier SCmA withdrew a net $345M in Q2 2021, closing 92 positions and reducing 146 holdings. Its most notable exit was Allogene Therapeutics, an estimated $18.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 16% a quarter earlier, followed by Communication Services and Financials.
Against the trend, Compagnie Lombard Odier SCmA opened a new position in Bilibili worth $9.73M.
- Compagnie Lombard Odier SCmA's largest Q2 2021 buy was Bilibili: 79,851 shares worth $9.73M.
- Compagnie Lombard Odier SCmA added most to Salesforce in Q2 2021, an estimated $46.3M increase.
- Compagnie Lombard Odier SCmA's biggest Q2 2021 reduction was Intellia Therapeutics, cutting an estimated $22M.
- Compagnie Lombard Odier SCmA fully exited Allogene Therapeutics in Q2 2021, selling an estimated $18.9M.
- Compagnie Lombard Odier SCmA's ten largest holdings make up 41% of its $4.55B portfolio in Q2 2021.
- Compagnie Lombard Odier SCmA opened 73 new positions and closed 92 in Q2 2021.
- Compagnie Lombard Odier SCmA's portfolio value rose 0.27% quarter-over-quarter to $4.55B.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2021, filed 15 Jul 2021.